Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Dirk Niemann"'
Autor:
David Baden, Sven Zukunft, Gema Hernandez, Nadine Wolgast, Sophie Steinhauser, Alexander Pohlmann, Christoph Schliemann, Jan-Henrik Mikesch, Bjorn Steffen, Tim Sauer, Maher Hanoun, Kerstin Schafer-Eckart, Stefan W. Krause, Mathias Hanel, Hermann Einsele, Edgar Jost, Tim H. Brummendorf, Sebastian Scholl, Andreas Hochhaus, Andreas Neubauer, Andreas Burchert, Martin Kaufmann, Dirk Niemann, Markus Schaich, Wolfgang Blau, Alexander Kiani, Martin Gorner, Ulrich Kaiser, Johannes Kullmer, Thomas Weber, Wolfgang E Berdel, Gerhard Ehninger, Carsten Muller-Tidow, Uwe Platzbecker, Hubert Serve, Martin Bornhauser, Christoph Rollig, Claudia D Baldus, Lars Fransecky
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
In newly diagnosed acute myeloid leukemia, immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pre-therapeutic risk factors. We explored the impact of time from
Externí odkaz:
https://doaj.org/article/a18a7d664edd4e4590ac8fdec959dd27
Autor:
Marius Bill, Leo Ruhnke, Sven Zukunft, Silvia Schäfer, Jan-Niklas Eckardt, Sebastian Stasik, Maher Hanoun, Thomas Schroeder, Lars Fransecky, Björn Steffen, Stefan W. Krause, Sebastian Scholl, Andreas Hochhaus, Tim Sauer, Sabrina Kraus, Kerstin Schäfer-Eckart, Martin Kaufmann, Edgar Jost, Tim H Brümmendorf, Christoph Schliemann, Jan-Henrik Mikesch, Utz Krug, Mathias Hänel, Anke Morgner, Markus Schaich, Andreas Neubauer, Roland Repp, Dirk Niemann, Ruth Seggewiss-Bernhardt, Achim Meinhardt, Johannes Kullmer, Ulrich Kaiser, Wolfgang Blau, Alexander Kiani, Götz Ulrich Grigoleit, Aristoteles Giagounidis, Alexander Wurm, Heidi Altmann, Jan Moritz Middeke, Johannes Schetelig, Carsten Müller-Tidow, Friedrich Stölzel, Claudia Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhäuser, Christian Thiede, Christoph Röllig
Publikováno v:
HemaSphere, Vol 7, p e72156a7 (2023)
Externí odkaz:
https://doaj.org/article/4f60a7cb94af465e91534560db0cc6e5
Autor:
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Tim Sauer, Martina Crysandt, Andreas Rank, Dirk Behringer, Lino Teichmann, Martin Görner, Ralf-Ulrich Trappe, Christoph Röllig, Stefan Krause, Maher Hanoun, Olaf Hopfer, Gerhard Held, Sebastian Buske, Lars Fransecky, Sabine Kayser, Christoph Schliemann, Kerstin Schaefer-Eckart, Yousef Al-Fareh, Jörg Schubert, Thomas Geer, Martin Kaufmann, Arne Brecht, Dirk Niemann, Meinhard Kieser, Martin Bornhäuser, Uwe Platzbecker, Hubert Serve, Claudia D. Baldus, Carsten Müller-Tidow, Richard F. Schlenk
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-13 (2021)
Abstract Background Overall survival remains poor in older patients with acute myeloid leukemia (AML) with less than 10% being alive after 5 years. In recent studies, a significant improvement in event-free, relapse-free and overall survival was show
Externí odkaz:
https://doaj.org/article/de39e7989b1540d2a1eb5143a0cffc57
Autor:
Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, Friedrich Stölzel, Cristina Gil, H. Christian Reinhardt, Eliana Aguiar, Kerstin Schäfer-Eckart, Juan Miguel Bergua Burgues, Björn Steffen, Teresa Bernal, Stefan W. Krause, Rosalía Riaza, Christoph Schliemann, Jose Cervera, Martin Kaufmann, Laura Torres-Miñana, Mathias Hänel, Evelyn Acuña-Cruz, Edgar Jost, Jesus Lorenzo Algarra, Martina Crysandt, Lars Fransecky, Javier Cornago-Navascues, Sabrina Kraus, Joaquin Martinez-Lopez, Hermann Einsele, Dirk Niemann, Andreas Neubauer, Ruth Seggewiß-Bernhardt, Sebastian Scholl, Stefan A. Klein, Christoph Schmid, Markus Schaich, Martin Schmidt-Hieber, Sven Zukunft, Anthony D. Ho, Uwe Platzbecker, Claudia D. Baldus, Carsten Müller-Tidow, Christian Thiede, Martin Bornhäuser, Hubert Serve, Mark Levis, Pau Montesinos, Christoph Röllig, Richard F. Schlenk
Publikováno v:
Haematologica, Vol 108, Iss 1 (2022)
We retrospectively studied 125 patients with acute myeloid leukemia and trisomy 4 (median age at diagnosis, 58 years; range, 16-77 years) treated between 2000 and 2019 within a multicenter study. Trisomy 4 was the sole abnormality in 28 (22%) patient
Externí odkaz:
https://doaj.org/article/e4e11f5318024c99a75f248fe4ef3498
Autor:
Sabine Kayser, Richard F. Schlenk, Delphine Lebon, Martin Carre, Katharina S. Götze, Friedrich Stölzel, Ana Berceanu, Kerstin Schäfer-Eckart, Pierre Peterlin, Yosr Hicheri, Ramy Rahme, Emmanuel Raffoux, Fatiha Chermat, Stefan W. Krause, Walter E. Aulitzky, Sophie Rigaudeau, Richard Noppeney, Celine Berthon, Martin Görner, Edgar Jost, Philippe Carassou, Ulrich Keller, Corentin Orvain, Thorsten Braun, Colombe Saillard, Ali Arar, Volker Kunzmann, Mathieu Wemeau, Maike de Wit, Dirk Niemann, Caroline Bonmati, Carsten Schwänen, Julie Abraham, Ahmad Aljijakli, Stephanie Haiat, Alwin Krämer, Albrecht Reichle, Martina Gnadler, Christophe Willekens, Karsten Spiekermann, Wolfgang Hiddemann, Carsten Müller-Tidow, Christian Thiede, Christoph Röllig, Hubert Serve, Martin Bornhäuser, Claudia D. Baldus, Eva Lengfelder, Pierre Fenaux, Uwe Platzbecker, Lionel Adès
Publikováno v:
Haematologica, Vol 106, Iss 12 (2021)
The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic
Externí odkaz:
https://doaj.org/article/d1110d66d5bd4ca48add2308757b49eb
Autor:
Christoph Röllig, Björn Steffen, Christoph Schliemann, Jan-Henrik Mikesch, Nael Alakel, Regina Herbst, Mathias Haenel, Richard Noppeney, Maher Hanoun, Martin Kaufmann, Zdenek Racil, Kerstin Schäfer-Eckart, Tim Sauer, Andreas Neubauer, Claudia D. Baldus, Jolana Mertova, Edgar Jost, Dirk Niemann, Jan Novak, Stefan W. Krause, Sebastian Scholl, Andreas Hochhaus, Gerhard Held, Tomáš Szotkowski, Christoph Schmid, Andreas Rank, Lars Fransecky, Michael Kramer, Frank Fiebig, Annett Haake, Friedrich Stoelzel, Johannes Schetelig, Jan Moritz Middeke, Uwe Platzbecker, Christian Thiede, Carsten Müller-Tidow, Wolfgang E. Berdel, Hubert Serve, Gerhard Ehninger, Jiří Mayer, Martin Bornhaeuser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8e5ea5166b173be8df1cc2ec4eb10ec
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/99704
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/99704
Autor:
Maher Hanoun, Leo Ruhnke, Michael Kramer, Christine Hanoun, Kerstin Schäfer-Eckart, Björn Steffen, Tim Sauer, Stefan Krause, Christoph Schliemann, Jan-Henrik Mikesch, Martin Kaufmann, Mathias Haenel, Edgar Jost, Tim Bruemmendorf, LArs Fransecky, Sabrina Kraus, Hermann Einsele, Dirk Niemann, Andreas Neubauer, Johannes Kullmer, Ruth Seggewiss-Bernhard, Martin Goerner, Gerhard Held, Ulrich Kaiser, Sebastian Scholl, Andreas Hochhaus, Hans Reinhardt, Uwe Platzbecker, Claudia Baldus, Carsten Müller-Tidow, Martin Bornhäuser, Hubert Serve, Christoph Röllig
Higher doses of cytarabine appear to improve long-term outcome in acute myeloid leukemia (AML), in particular for younger patients. To this end, the optimal dosage of single agent cytarabine in consolidation therapy remains elusive. Here, we assessed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3efddf187af967c6dd3436ccf5d34d1
https://doi.org/10.21203/rs.3.rs-1704919/v1
https://doi.org/10.21203/rs.3.rs-1704919/v1
Autor:
José Cervera, Javier Cornago Navascués, Joaquin Martinez-Lopez, Juan Miguel Bergua Burgues, Sabrina Kraus, Ruth Seggewiss-Bernhardt, Teresa Bernal, Carsten Müller-Tidow, Martin Bornhäuser, H. Christian Reinhardt, Jesús Lorenzo Algarra, Andreas Neubauer, Richard F. Schlenk, Maher Hanoun, Eliana Aguiar, Martin Kaufmann, Björn Steffen, Christian Thiede, Dirk Niemann, Cristina Gil, Edgar Jost, Rosalia Riaza, Sabine Kayser, Hubert Serve, David Martínez-Cuadrón, Anthony D. Ho, Pau Montesinos, Mark J. Levis, Kerstin Schäfer-Eckart, Laura Torres, Markus Schaich, Hermann Einsele, Friedrich Stölzel, Christoph Röllig, Christoph Schmid, Lars Fransecky, Martin Schmidt-Hieber, Evelyn Acuña-Cruz, Claudia D. Baldus, Sebastian Scholl, Stefan W. Krause, Martina Crysandt, Mathias Haenel, Uwe Platzbecker, Stefan Klein, Christoph Schliemann
Publikováno v:
HAEMATOLOGICA
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Background: Trisomy 4 is a recurrent but rare cytogenetic abnormality reported in patients with acute myeloid leukemia (AML). The prognostic significance of this abnormality in AML patients is not clear. Prognosis of AML patients with trisomy 4 seems
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40029ad994661a2a6c935359ec13e385
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9267
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9267
Autor:
Martin Kaufmann, Pavel Zak, Björn Steffen, Maher Hanoun, Johannes Schetelig, Kerstin Schäfer-Eckart, Christoph Schliemann, Maxi Wass, Uwe Platzbecker, Gerhard Ehninger, Andreas Neubauer, Zdenek Racil, Edgar Jost, Carsten Müller-Tidow, Christian Thiede, Tomáš Szotkowski, Jiri Mayer, Nael Alakel, Wolfgang E. Berdel, Gerhard Held, Jolana Mertova, Frank Fiebig, Dirk Niemann, Richard Noppeney, Hubert Serve, Stefan W. Krause, Andreas Rank, Sebastian Buske, Alwin Krämer, Christoph Röllig, Regina Herbst, Annett Haake, Claudia D. Baldus, Sebastian Scholl, Jan Novák, Stefani Parmentier, Michael Kramer, Martin Bornhäuser
Publikováno v:
Blood. 136:1-3
Background Double induction using two subsequent 7+3 regimens of cytarabine plus anthracycline is commonly performed in AML patients with an adequate performance status in order to maximize dose intensity upfront. However, for patients with a good ea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5f0f5ecd0f9173acb926129d5a0dc14
https://doi.org/10.1182/blood-2020-140246
https://doi.org/10.1182/blood-2020-140246
Autor:
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Tim Sauer, Martina Crysandt, Andreas Rank, Dirk Behringer, Lino Teichmann, Martin Görner, Ralf Ulrich Trappe, Christoph Röllig, Stefan Krause, Maher Hanoun, Olaf Hopfer, Gerhard Held, Sebastian Buske, Lars Fransecky, Sabine Kayser, Christoph Schliemann, Kerstin Schaefer-Eckart, Yousef Al-Fareh, Jörg Schubert, Thomas Geer, Martin Kaufmann, Arne Brecht, Dirk Niemann, Meinhard Kieser, Martin Bornhäuser, Uwe Platzbecker, Hubert Serve, Claudia D. Baldus, Carsten Müller-Tidow, Richard F. Schlenk
BackgroundOverall survival remains poor in older patients with acute myeloid leukemia (AML) with less than 10% being alive after five years. In recent studies, a significant improvement in event-free, relapse-free and overall survival was shown by ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed728886ae6e268d15fa81e7e874bc4d
https://doi.org/10.21203/rs.3.rs-470951/v1
https://doi.org/10.21203/rs.3.rs-470951/v1